EASL 2015 Conference bulletinsConference news, available in English, French, Portuguese, Russian and Spanish. Dr Ira Jacobson of Weill-Cornell Medical College presents results of the C-SALT study. Photo by Liz Highleyman, hivandhepatitis.comAdvanced cirrhosisMerck HCV combination achieves 90% cure in advanced cirrhosis. Jean-Michel Pawlotsky presenting at the International Liver Congress. Photo by Liz Highleyman, hivandhepatitis.comNew EASL guidelinesEuropean liver specialists prioritise interferon-free hepatitis C treatment. infohep news Treatment outcomes Liver function and survival improve after treatment with Viekirax + Exviera regimen Liz Highleyman / 27 June 2015 People with hepatitis C who were treated with AbbVie's Viekirax plus Exviera or '3D' regimen saw improvements in liver function biomarkers, had better quality of life and had increased survival compared to ... Sex between men Hepatitis C treatment could halve HCV transmission among gay men in UK over 10 years Keith Alcorn / 24 June 2015 Access to more effective hepatitis C treatment could halve new infections among men who have sex with men in the United Kingdom over the next decade, according to a modelling study presented ... Interferon treatment for HBV Using interferon with hepatitis B antivirals raises likelihood of HBsAg loss Liz Highleyman / 15 June 2015 Treating chronic hepatitis B with tenofovir plus pegylated interferon for 48 weeks resulted in a higher rate of hepatitis B surface antigen (HBsAg) clearance than either drug taken alone, though the response rate ... Alternative treatments Milk thistle may improve steatohepatitis, capsaicin from chilli peppers may slow fibrosis Liz Highleyman / 10 June 2015 People who used silymarin, derived from the milk thistle plant, experienced a resolution of non-alcoholic steatohepatitis (NASH) and a reduction in liver fibrosis in a randomised, placebo-controlled trial, researchers reported at the European ... Prisoners Hepatitis C treatment for people in prison may be highly cost-effective in England Keith Alcorn / 08 June 2015 Reducing the duration of direct-acting antiviral treatment for hepatitis C will make treatment for people in prison in England highly cost-effective, and could provide an important opportunity for providing access to hepatitis C ... Hepatitis B patients on long-term entecavir or tenofovir have low mortality, but liver cancer remains a risk Liz Highleyman / 03 June 2015 More than 95% of people with chronic hepatitis B were still alive after five years on antiviral therapy with entecavir (Baraclude) or tenofovir (Viread) and most deaths were due to non-liver-related causes, according ... Antiviral therapy Stopping tenofovir is safe for people with hepatitis B on long-term therapy Liz Highleyman / 02 June 2015 Most people with hepatitis B virus (HBV) who stopped taking tenofovir (Viread) after more than three years on treatment had good outcomes, according to a presentation at the recent European Association for the ... Hepatitis B and C co-infection linked to worse liver fibrosis than hepatitis B alone Liz Highleyman / 01 June 2015 People with both hepatitis B virus (HBV) and hepatitis C virus (HCV) co-infection may experience more rapid and severe liver disease progression than those with hepatitis B alone, though HBV/HCV co-infection did ... Genotype 1b Paritaprevir and ombitasvir are effective for Japanese patients with HCV genotype 1b Keith Alcorn / 26 May 2015 Viekirax (ombitasvir and paritaprevir with ritonavir) was highly effective in curing hepatitis C without the accompaniment of dasabuvir (Exviera) in Japanese people with genotype 1b hepatitis C infection in the GIFT 1 trial, ... Hepatitis delta Prenylation inhibitor lonafarnib lowers hepatitis delta viral load during therapy Liz Highleyman / 22 May 2015 Lonafarnib, a farnesyl transferase inhibitor that interferes with viral assembly, reduced hepatitis delta virus (HDV) levels by more than 3 log10 in a phase 2 study presented at the European Association for ... View more > Editors' picks from other sources Cirrhosis Dr. E Lebovics: Post-EASL 2015 HCV Interview American Journal of Medicine Hepatitis C Resource Center / 02 June 2015 Epidemiology Gilead uses Georgia as free-drug testbed for hepatitis C elimination Reuters / 27 April 2015 Interferon-free regimens Merck and Gilead square off in battle of the next-next-gen hep C combos Fierce Biotech / 24 April 2015 View more > Other pages in this section Latest news All the news Conference news Email bulletin archive